Rebone Maboa

Dados Biográficos

ID9019620
NOMERebone Maboa
PRENOMESRebone
SOBRENOMEMaboa
ASSINATURAMABOA R
ORCID0000-0002-6894-8047
VERIFICADOSim
TOTAL DE OBRAS2
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR2
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2023
ANO MAIS RECENTE DE PUBLICAÇÃO2024
ÍNDICE H0

  • Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa

    Open AccessNigel Garrett, Tarylee Reddy et al.ARTICLEPLOS Global Public Health2024

    Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…

  • Post-Covid symptom profiles and duration in a global convalescent Covid-19 observational cohort

    Open AccessShelly Karuna, Jorge A Gallardo-Cartagena et al.ARTICLEJournal of Global Health2023

    Background: Post-COVID conditions are characterised by persistent symptoms that negatively impact quality of life after SARS-CoV-2 diagnosis. While post-COVID risk factors and symptoms have been extensively described in localised regions, especially in the global north, post-COVID conditions remain poorly understood globally. The global, observational cohort study HVTN 405/HPTN 1901 characterises the convalescent course of SARS-CoV-2 infection am…